ICD-10 R06.2 is officially defined as "Wheezing." code R06.2 is referenced in 6 tracked payer policy changes from Health Net and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code R06.2 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
CalViva Health updated multiple medical policies for Q1 2020, affecting prior authorization requirements, coverage criteria, and billing codes across numerous specialties. Key changes include new coronavirus testing guidelines, updated DME criteria, revised surgical procedure coverage, and modified prior authorization requirements for various treatments.
Health Net updated multiple medical policies in Q1 2020, including new prior authorization requirements, coverage changes for various procedures, and updated billing codes. Key changes include new coronavirus testing guidelines, revised DME criteria, and updated coverage for procedures like facet joint injections and nerve blocks.
Health Net updated multiple medical policies for Q1 2020, including new COVID-19 testing guidelines, changes to prior authorization requirements for various procedures, and updates to coverage criteria for DME, nerve blocks, transplants, and other services. Most notably, several procedures were reclassified as not medically necessary or investigational, affecting billing and coverage.
Aetna's Clinical Policy Bulletin 0813 (reviewed 2026-10-28) classifies computerized wheeze detectors—including the PulmoTrack, Personal Wheezometer, and VRIxp devices—as experimental, investigational, or unproven for diagnostic evaluation of lung sounds, cough, and all other indications due to insufficient evidence of effectiveness. Claims for these devices will be denied for Aetna members.
Aetna Clinical Policy Bulletin 0667 on esophageal and airway pH monitoring, reviewed 2026-10-07, considers esophageal pH monitoring medically necessary for listed indications, such as refractory reflux in members with chest pain after cardiac evaluation, and for evaluating vomiting in infants up to 3 months of age. The policy considers multi-channel intraluminal impedance testing medically necessary for certain reflux and dysphagia indications, and considers airway pH monitoring, pharyngeal pH monitoring and airway impedance measurement experimental, investigational or unproven. This is an older source dated 2026-10-07, which is historical material, and it states no effective date.
Aetna Clinical Policy Bulletin 0667 covers esophageal and airway pH monitoring. Aetna considers esophageal pH monitoring and multichannel intraluminal impedance medically necessary for the indications listed in the policy, and considers other uses experimental, investigational or unproven. The source does not state an effective date or describe a specific change.
Watch R06.2
Get one email when a payer policy names R06.2, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.